Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 11, 2013, Pages

  Britschgi, Adrian ^a   Bill, Anke ^b   Brinkhaus, Heike ^a   Rothwell, Christopher ^b   Clay, Ieuan ^c   Duss, Stephan ^a   Rebhan, Michael ^c   Raman, Pichai ^b   Guy, Chantale T ^b   Wetzel, Kristie ^b   George, Elizabeth ^b   Popa, M Oana ^b   Lilley, Sarah ^b   Choudhury, Hedaythul ^b   Gosling, Martin ^b   Wang, Louis ^b   Fitzgerald, Stephanie ^b   Borawski, Jason ^b   Baffoe, Jonathan ^b   Labow, Mark ^b   Gaither, L Alex ^b   Bentires Alj, Mohamed ^a   more..

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CaCCinh A01; ESCC; HNSCC; Ion channel; TMEM16A

Indexed keywords

ANOCTAMIN 1; CALCIUM ACTIVATED CHLORIDE CHANNEL; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL LINE, TUMOR; CELL SURVIVAL; CHLORIDE CHANNELS; CHROMOSOMES, HUMAN, PAIR 11; ENZYME ACTIVATION; FEMALE; GENE AMPLIFICATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875035786     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217072110     Document Type: Article

References (59)

1. Jonkers J, Berns A (2004) Oncogene addiction: Sometimes a temporary slavery. Cancer Cell 6(6):535-538.
2. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239): 719-724.
3. West RB, et al. (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165(1):107-113.
4. Kashyap MK, et al. (2009) Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther 8(1):36-46.
5. Carles A, et al. (2006) Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene 25(12):1821-1831.
6. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78(3):323-335.
7. Jönsson G, et al. (2010) Genomic subtypes of breast cancer identified by arraycomparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 12(3):R42.
8. Rodrigo JP, et al. (2009) Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 217 (4):516-523.
9. Sawey ET, et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19(3):347-358.
10. Schuuring E (1995) The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 159(1):83-96.
11. Debnath J, et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111(1):29-40.
12. Velasco-Velázquez MA, et al. (2011) Examining the role of cyclin D1 in breast cancer. Future Oncol 7(6):753-765.
13. Gleich LL, Li YQ, Wang X, Stambrook PJ, Gluckman JL (1999) Variable genetic alterations and survival in head and neck cancer. Arch Otolaryngol Head Neck Surg 125(9):949-952.
14. Vielba R, et al. (2003) p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 113(1):167-172.
15. Holm K, et al. (2012) Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Res Treat 133(2):583-594.
16. Jin C, et al. (2006) Molecular cytogenetic characterization of the 11q13 amplicon in head and neck squamous cell carcinoma. Cytogenet Genome Res 115(2):99-106.
17. Huang X, Gollin SM, Raja S, Godfrey TE (2002) High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 99(17):11369-11374.
18. Liu W, Lu M, Liu B, Huang Y, Wang K (2012) Inhibition of Ca(2+)-activated Cl(-) channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma. Cancer Lett 326(1):41-51.
19. Yang YD, et al. (2008) TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455(7217):1210-1215.
20. Schroeder BC, Cheng T, Jan YN, Jan LY (2008) Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134(6):1019-1029.
21. Caputo A, et al. (2008) TMEM16A, a membrane protein associated with calciumdependent chloride channel activity. Science 322(5901):590-594.
22. Huang F, Wong X, Jan LY (2012) International Union of Basic and Clinical Pharmacology. LXXXV: Calcium-activated chloride channels. Pharmacol Rev 64(1): 1-15.
23. Cho H, et al. (2012) The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci 15(7):1015-1021.
24. NamkungW, Phuan PW, Verkman AS (2011) TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J Biol Chem 286(3):2365-2374.
25. De La Fuente R, Namkung W, Mills A, Verkman AS (2008) Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel. Mol Pharmacol 73(3):758-768.
26. Kumar S, Namkung W, Verkman AS, Sharma PK (2012) Novel 5-substituted benzyloxy-2-arylbenzofuran-3-carboxylic acids as calcium activated chloride channel inhibitors. Bioorg Med Chem 20(14):4237-4244.
27. Ayoub C, et al. (2010) ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines. Br J Cancer 103(5):715-726.
28. Duvvuri U, et al. (2012) TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res 72(13):3270-3281.
29. Ruiz C, et al. (2012) Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis. PLoS ONE 7(8): e43265.
30. Ishizuka T, et al. (2002) Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 296(1):152-155.
31. Chung CC, et al. (2011) Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet 20(14):2869-2878.
32. Hicks J, et al. (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16(12):1465-1479.
33. Yano S, Tokumitsu H, Soderling TR (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396(6711):584-587.
34. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
35. Arcangeli A, et al. (2009) Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem 16(1):66-93.
36. Schmitt JM, Smith S, Hart B, Fletcher L (2011) CaM Kinase control of AKT and LNCaP cell survival. J Cell Biochem.
37. Swulius MT, Waxham MN (2008) Ca(2+)/calmodulin-dependent protein kinases. Cell Mol Life Sci 65(17):2637-2657.
38. Cipolletta E, et al. (2010) Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology 151(6):2747-2759.
39. Rosen LB, Greenberg ME (1996) Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci USA 93(3):1113-1118.
40. Tahara S, et al. (2001) Potassium channel blocker activates extracellular signalregulated kinases through Pyk2 and epidermal growth factor receptor in rat cardiomyocytes. J Am Coll Cardiol 38(5):1554-1563.
41. Tsai W, Morielli AD, Peralta EG (1997) The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J 16(15): 4597-4605.
42. Zanou N, et al. (2012) Trpc1 ion channel modulates phosphatidylinositol 3-kinase/Akt pathway during myoblast differentiation and muscle regeneration. J Biol Chem 287(18):14524-14534.
43. Horiuchi K, et al. (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18(1):176-188.
44. Bradshaw JM (2010) The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal 22(8):1175-1184.
45. Chatterjee S, et al. (2012) Membrane depolarization is the trigger for PI3K/Akt activation and leads to the generation of ROS. Am J Physiol Heart Circ Physiol 302(1): H105-H114.
46. Peppelenbosch MP, Tertoolen LG, den Hertog J, de Laat SW (1992) Epidermal growth factor activates calcium channels by phospholipase A2/5-lipoxygenase- mediated leukotriene C4 production. Cell 69(2):295-303.
47. Jeulin C, Seltzer V, Bailbé D, Andreau K, Marano F (2008) EGF mediates calciumactivated chloride channel activation in the human bronchial epithelial cell line 16HBE14o-: Involvement of tyrosine kinase p60c-src. Am J Physiol Lung Cell Mol Physiol 295(3):L489-L496.
48. Mroz MS, Keely SJ (2012) Epidermal growth factor chronically upregulates Ca(2+)-dependent Cl(-) conductance and TMEM16A expression in intestinal epithelial cells. J Physiol 590(Pt 8):1907-1920.
49. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ (1995) Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92(15):6981-6985.
50. Perez-Cornejo P, et al. (2012) Anoctamin 1 (Tmem16A) Ca2+-activated chloride channel stoichiometrically interacts with an ezrin-radixin-moesin network. Proc Natl Acad Sci USA 109(26):10376-10381.
51. Hama T, et al. (2009) Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14(9):900-908.
52. Wheeler S, et al. (2012) Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18(8):2278-2289.
53. Magkou C, et al. (2008) Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 10(3):R49.
54. Du L, Shen J, Weems A, Lu SL (2012) Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012:450179.
55. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9-22.
56. Rothenberg SM, Ellisen LW (2012) The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 122(6):1951-1957.
57. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
58. Wickham H (2011) The split-apply-combine strategy for data analysis. J Stat Softw40(1): 1-29.
59. Mathes C, Friis S, Finley M, Liu Y (2009) QPatch: The missing link between HTS and ion channel drug discovery. Comb Chem High Throughput Screen 12(1):78-95.